tetano
Editor, Senior Moderator
Int J Pharm
. 2022 Jul 13;122021.
doi: 10.1016/j.ijpharm.2022.122021. Online ahead of print.
Formulation of Dry Powders of Vaccines Containing MF59 or AddaVax by Thin-Film Freeze-Drying: Towards a dry powder universal flu vaccine
Khaled AboulFotouh[SUP] 1 [/SUP], Naoko Uno[SUP] 2 [/SUP], Haiyue Xu[SUP] 3 [/SUP], Chaeho Moon[SUP] 3 [/SUP], Sawittree Sahakijpijarn[SUP] 3 [/SUP], Dale J Christensen[SUP] 4 [/SUP], Gregory J Davenport[SUP] 4 [/SUP], Chris Cano[SUP] 4 [/SUP], Ted M Ross[SUP] 5 [/SUP], Robert O Williams Iii[SUP] 6 [/SUP], Zhengrong Cui[SUP] 7 [/SUP]
Affiliations
Abstract
MF59® is an oil-in-water (O/W) nanoemulsion-based vaccine adjuvant that is often used in seasonal and pandemic influenza vaccines. We explored the feasibility of developing dry powders of vaccines adjuvanted with MF59 or AddaVax™, a preclinical grade equivalent of MF59 with the same composition and droplet size as MF59, by thin-film freeze-drying (TFFD). Liquid AddaVax alone was successfully converted to a dry powder by TFFD using trehalose as a stabilizing agent while maintaining the droplet size distribution of AddaVax after it was reconstituted. TFFD was then applied to convert liquid AddaVax-adjuvanted vaccines containing either a model antigen (e.g., ovalbumin) or mono-, bi-, and tri-valent recombinant hemagglutinin (rHA) protein-based H1 and/or H3 (universal) influenza vaccine candidates, as well as the MF59-containing Fluad® Quadrivalent influenza vaccine to dry powders. Both antigens and stabilizing agents affected the physical properties of the vaccines (e.g., mean particle size and particle size distribution) after being subjected to TFFD. Importantly, the integrity and hemagglutination activity of the rHA antigens did not significantly change and the immunogenicity of reconstituted influenza vaccine candidates was maintained when evaluated in a mouse model. The vaccine dry powder was not sensitive to repeated freezing-and-thawing, in contrast to its liquid counterpart. It is concluded that TFFD can be applied to convert liquid vaccines containing MF59 or AddaVax to dry powders while maintaining the immunogenicity of the vaccines. Ultimately, TFFD technology may be used to prepare dry powders of multivalent universal influenza vaccines.
Keywords: Vaccine; adjuvant; dry powder; freeze-drying; immunogenicity; influenza; nanoemulsion; solid state; thermal analysis.
. 2022 Jul 13;122021.
doi: 10.1016/j.ijpharm.2022.122021. Online ahead of print.
Formulation of Dry Powders of Vaccines Containing MF59 or AddaVax by Thin-Film Freeze-Drying: Towards a dry powder universal flu vaccine
Khaled AboulFotouh[SUP] 1 [/SUP], Naoko Uno[SUP] 2 [/SUP], Haiyue Xu[SUP] 3 [/SUP], Chaeho Moon[SUP] 3 [/SUP], Sawittree Sahakijpijarn[SUP] 3 [/SUP], Dale J Christensen[SUP] 4 [/SUP], Gregory J Davenport[SUP] 4 [/SUP], Chris Cano[SUP] 4 [/SUP], Ted M Ross[SUP] 5 [/SUP], Robert O Williams Iii[SUP] 6 [/SUP], Zhengrong Cui[SUP] 7 [/SUP]
Affiliations
- PMID: 35842082
- DOI: 10.1016/j.ijpharm.2022.122021
Abstract
MF59® is an oil-in-water (O/W) nanoemulsion-based vaccine adjuvant that is often used in seasonal and pandemic influenza vaccines. We explored the feasibility of developing dry powders of vaccines adjuvanted with MF59 or AddaVax™, a preclinical grade equivalent of MF59 with the same composition and droplet size as MF59, by thin-film freeze-drying (TFFD). Liquid AddaVax alone was successfully converted to a dry powder by TFFD using trehalose as a stabilizing agent while maintaining the droplet size distribution of AddaVax after it was reconstituted. TFFD was then applied to convert liquid AddaVax-adjuvanted vaccines containing either a model antigen (e.g., ovalbumin) or mono-, bi-, and tri-valent recombinant hemagglutinin (rHA) protein-based H1 and/or H3 (universal) influenza vaccine candidates, as well as the MF59-containing Fluad® Quadrivalent influenza vaccine to dry powders. Both antigens and stabilizing agents affected the physical properties of the vaccines (e.g., mean particle size and particle size distribution) after being subjected to TFFD. Importantly, the integrity and hemagglutination activity of the rHA antigens did not significantly change and the immunogenicity of reconstituted influenza vaccine candidates was maintained when evaluated in a mouse model. The vaccine dry powder was not sensitive to repeated freezing-and-thawing, in contrast to its liquid counterpart. It is concluded that TFFD can be applied to convert liquid vaccines containing MF59 or AddaVax to dry powders while maintaining the immunogenicity of the vaccines. Ultimately, TFFD technology may be used to prepare dry powders of multivalent universal influenza vaccines.
Keywords: Vaccine; adjuvant; dry powder; freeze-drying; immunogenicity; influenza; nanoemulsion; solid state; thermal analysis.